MARLBOROUGH, Mass.--(BUSINESS WIRE)--Oct. 25, 2005--Sepracor Inc. (Nasdaq: SEPR) today announced its consolidated financial results for the third quarter of 2005. For the three months ended September 30, 2005, Sepracor’s consolidated revenues were $205.7 million, of which revenues from pharmaceutical product sales were $193.4 million ($92.5 million for sales of XOPENEX(R) brand levalbuterol HCl Inhalation Solution and $100.9 million for sales of LUNESTA(TM) brand eszopiclone). The net loss for the third quarter of 2005 was $2.2 million, or $0.02 per share. Included in the third quarter 2005 results is a gain on the sale of Vicuron stock of $18.3 million, or $0.17 per share, as a result of Pfizer’s acquisition of Vicuron. These consolidated results compare with consolidated revenues of $80.1 million, of which revenues from pharmaceutical product sales (XOPENEX Inhalation Solution) were $60.1 million, for the third quarter of 2004. The net loss for the third quarter of 2004 was $130.4 million, or $1.40 per share.
